Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISA101 and Nivolumab in HPV-16 Positive Tumors
NCT02426892Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2015
- Primary completion
- Nov 2021
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of SLP-HPV-01 in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2015; status: completed.
02
Drugs
SLP-HPV-01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02426892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426892.